|Videos|June 10, 2017

Keeping Patient Wellbeing at the Center of Outbreak Investigation

Arjun Srinivasan, MD, explains how healthcare officials can keep the patient at the center of outbreak investigations.

Arjun Srinivasan, MD, associate director, Healthcare-associated Infection Prevention Programs, Centers for Disease Control and Prevention, explains how healthcare officials can keep the patient at the center of outbreak investigations.

Interview Transcript (slightly modified for readability)

“The patient is at the center of what we do when we investigate an outbreak. The reason that we’re investigating the outbreak is to protect patients from harm. Patients need to know, they need to be kept informed about what’s going on.

So, either the patient or the loved one needs to know [the following]: What is the outbreak? What’s the nature of it? Most importantly, they need to know what steps are being taken to keep them safe, [and] what are you doing to manage if they had an infection that was part of the outbreak. How are they treating that infection? What are we doing to make sure that they are treated? What are we doing to protect other patients? What are we doing to make sure that the care we deliver is safe?”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.